Cortes Underscores Rationale for BCMA-Directed Therapy in Multiple Myeloma

Jessica Hergert
Published: Thursday, Mar 19, 2020
Jorge E. Cortes, MD

Jorge E. Cortes, MD

A significant uptick in investigational research regarding BCMA-directed therapies, specifically in the form of CAR T-cell therapies and antibody-drug conjugates (ADCs), has been underway to tailor therapies for patients with multiple myeloma and, in turn, enhance response rates, explained Jorge E. Cortes, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication